The MiniMed 780G system is Canada's only insulin pump that automatically adjusts and corrects every five minutes, and its auto-correction algorithm delivers both background and bolus delivery

780Gsystem-G3S-sensor

Medtronic’s next-gen MiniMed 780G system. (Credit: Medtronic)

Medtronic Canada announced that Health Canada has granted a license to its MiniMed 780G insulin pump system for use by people living with type 1 diabetes.

The system is indicated for the management of type 1 diabetes in people, aged seven to 80 years, with a total daily insulin dose of eight units per day or more.

The medical technology company designed the MiniMed 780G system using its advanced SmartGuard technology to prevent highs and lows in insulin delivery.

It allows users to personalise glucose delivery, by adjusting the setting as low as 5.5 mmol/L, lower than any other advanced hybrid closed loop (AHCL) system

The system also allows the patients to stabilise their blood sugar levels, and reduces up to 96% need for injections for those using insulin pens alone.

MiniMed 780G system with an advanced hybrid closed loop is the first and only insulin pump system in Canada that can automatically adjust every five minutes, said Medtronic.

Medtronic Canada endocrinology senior director Laura Cameron said: “Our latest system is designed for real life by increasing automation for an easier way to help stabilize sugar levels.

“Mealtimes can be stressful, especially when you’re on the go, so we’re pleased to have designed an advanced algorithm that automatically covers for underestimated carbs with meal detection technology.”

Medtronic said that the MiniMed 780G system is designed such that it requires less input from the user, and simplifies day-to-day interactions with the pump.

Its Bluetooth connectivity feature allows users and their care partners to access real-time glucose data and trends using apps on compatible iOS and Android smartphones.

According to the ADAPT study data, MiniMed 780G showed significant improvement across all glycaemic metrics, compared to multiple daily injections and CGM (standard of care).

Cameron added: “Since launching the world’s first hybrid closed loop system, we continue to advance innovations that help people spend more time living their lives and less time worrying about their diabetes management.

“The MiniMed 780G system delivers on our ongoing commitment to reduce the burden of diabetes and improve control for patients.”

Medtronic Canada would allow the customers with existing MiniMed 770G insulin pumps to upgrade through a software update in the coming months, with plans to commercially launch the MiniMed 780G system hardware pump in 2023.